Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
XRad Therapeutics General Information
XRad Therapeutics’ lead candidate, XRD‑0394, is a first-in-class oral dual inhibitor of ATM and DNA-PK. It aims to enhance the effectiveness of radiation therapy in patients with metastatic, locally advanced or recurrent solid tumors. The company has initiated a Phase Ia open-label trial to evaluate safety and tolerability in combination with palliative radiation therapy at Memorial Sloan Kettering Cancer Center and Stanford Cancer Institute. Preclinical data suggest improved efficacy of radiotherapy by blocking key DNA repair enzymes[1][2][4][5]. No clinical efficacy results have been published yet.
Contact Information
Drug Pipeline
XRD-0394
Phase 1Key Partnerships
Aptus Clinical (CRO partner for early phase trials)[2][5], Catalyst Clinical Research (CRO support)[5]
XRad Therapeutics Funding
No funding data available
To view XRad Therapeutics's complete valuation and funding history, request access »